A nano-disperse ferritin-core mimetic that efficiently corrects anemia without luminal iron redox activity

Jonathan J Powell, Sylvaine F A Bruggraber, Nuno Faria, Lynsey K Poots, Nicole Hondow, Timothy J Pennycook, Gladys O Latunde-Dada, Robert J Simpson, Andy P Brown, Dora I A Pereira, Jonathan J Powell, Sylvaine F A Bruggraber, Nuno Faria, Lynsey K Poots, Nicole Hondow, Timothy J Pennycook, Gladys O Latunde-Dada, Robert J Simpson, Andy P Brown, Dora I A Pereira

Abstract

The 2-5 nm Fe(III) oxo-hydroxide core of ferritin is less ordered and readily bioavailable compared to its pure synthetic analogue, ferrihydrite. We report the facile synthesis of tartrate-modified, nano-disperse ferrihydrite of small primary particle size, but with enlarged or strained lattice structure (~2.7Å for the main Bragg peak versus 2.6Å for synthetic ferrihydrite). Analysis indicated that co-precipitation conditions can be achieved for tartrate inclusion into the developing ferrihydrite particles, retarding both growth and crystallization and favoring stabilization of the cross-linked polymeric structure. In murine models, gastrointestinal uptake was independent of luminal Fe(III) reduction to Fe(II) and, yet, absorption was equivalent to that of ferrous sulphate, efficiently correcting the induced anemia. This process may model dietary Fe(III) absorption and potentially provide a side effect-free form of cheap supplemental iron. From the clinical editor: Small size tartrate-modified, nano-disperse ferrihydrite was used for efficient gastrointestinal delivery of soluble Fe(III) without the risk for free radical generation in murine models. This method may provide a potentially side effect-free form iron supplementation.

Keywords: Bioavailability; Ferrihydrite; Iron deficiency anemia; Iron oxide; Oral iron.

Crown Copyright © 2014. Published by Elsevier Inc. All rights reserved.

Figures

Graphical abstract
Graphical abstract
Fig. S1
Fig. S1
combined
Fig. S2
Fig. S2
combined
Fig. S3
Fig. S3
combined
Fig. S4
Fig. S4
combined
Figure 1
Figure 1
Formation of tartrate-modified ferrihydrite in adipate buffer as a function of pH. (A) Dispersed or colloidal (i.e. nanoparticulate) iron, determined following centrifugation and ultrafiltration to remove soluble iron (main panel), and precipitated (i.e. agglomerated) iron, determined following centrifugation (inset). Closed squares show synthetic ferrihydrite precipitated from an Fe(III) chloride solution; open triangles show modified ferrihydrite precipitated from an Fe(III) chloride solution in the presence of sodium tartrate and adipate buffer (Fe/tartrate/adipate = 1:0.5:0.5); closed circles and open diamonds show ferrihydrite precipitated from an Fe(III) chloride solution in the presence of adipate alone (Fe/adipate = 1:0.5 and 1:1 respectively). (B) Percentage of nanoparticulate iron (main panel) and precipitated iron (inset) for the synthetic (closed squares) and tartrate-modified (open triangles) ferrihydrite materials (molar ratios as above) re-suspended in the original volume of aqueous solution. (A and B) All values are expressed as a percentage of total iron in the initial solution as described in Methods. (C) Simulated gastric dissolution at pH 1.0 of dried synthetic ferrihydrite (closed squares) and tartrate-modified ferrihydrite that had been precipitated in the presence of tartrate and adipate (open triangles), at molar ratios as above, and then dried. Data were obtained following 5-min ultrafiltration (3000 Da MWCO); data are mean ± SD, n = 3.
Figure 2
Figure 2
Structural characterization of the ferrihydrite. (A-D), High-angle annular dark-field, aberration-corrected, scanning transmission electron microscopy (HAADF-STEM) images of tartrate-modified ferrihydrite in tryptophan (A, B) or adipate buffer (C), and of synthetic (unmodified) ferrihydrite (D). Scale bars are 50 nm (A and C) or 2 nm (B and D). (E) X-ray diffraction patterns of synthetic ferrihydrite (black) and tartrate-modified ferrihydrite (red). Both patterns have peaks characteristic of ferrihydrite, with the synthetic ferrihydrite peaks centred at 35° and 62° 2θ (2.6 Å and 1.5 Å, respectively) and the tartrate-modified ferrihydrite peaks centered at 33° and 61° 2θ (2.7 Å and 1.5 Å, respectively), indicating expansion of the ferrihydrite lattice. Sodium tartrate is shown in green. Synthetic ferrihydrite was precipitated from an Fe(III) chloride solution and tartrate-modified ferrihydrite from an Fe(III) chloride solution in the presence of tartrate and tryptophan buffer (Fe/tartrate/tryptophan = 1:0.5:0.375). Excess ligand and buffer were removed from the modified material by ultrafiltration and washing prior to drying as described in Methods.
Figure 3
Figure 3
Fourier transform infrared (FTIR) spectroscopy of the ferrihydrite. Synthetic (unmodified) ferrihydrite is shown in black, tryptophan in blue, sodium tartrate in green and the tartrate-modified ferrihydrite is in red. Unique tartrate but no tryptophan signatures are revealed in the modified material. Synthetic and tartrate-modified ferrihydrite were prepared as per Figure 2.
Figure 4
Figure 4
Electron microscopy-based characterization of tartrate-modified ferrihydrite (red) against synthetic ferrihydrite (black). (A) Background-stripped electron energy-loss spectra (EELS) for the combined C K-edges (285 eV), Ca L2,3-edges (346 eV), O K-edges (530 eV) and Fe L2,3-edges (709.5 eV) normalized to the continuum intensity post the Fe L2,3-edges. (B) individual background-stripped Fe L2,3-edges. The unaltered shape of the Fe L2,3-edges indicates that the Fe−(O, OH)6 octahedra remain relatively unchanged after tartrate modification: i.e. the material remains Fe(III). (C and D) Bright-field transmission electron microscopy (TEM) images of synthetic ferrihydrite (C) and tartrate-modified ferrihydrite (D) agglomerates suspended over holes in the TEM support film (see supplementary methods for details of specimen preparation). Diffraction contrast from individual crystallites produces dark regions in the images, the size of which confirms the reduced crystallite size of the modified material. Synthetic ferrihydrite was precipitated from an Fe(III) chloride solution and tartrate-modified ferrihydrite from an Fe(III) chloride solution in the presence of tartrate and adipate buffer (Fe/tartrate/adipate = 1:0.5:0.5).
Figure 5
Figure 5
Comparative iron absorption and bioavailability of ligand-modified ferrihydrite. (A) Effect of ferrozine on the absorption of soluble ferric iron (i.e. Fe(III) NTA) and nanoparticulate, tartrate-modified ferrihydrite (i.e. LM-Fh) in male CD1 mice. Mice were orally gavaged with 59Fe-labeled compounds with (open bars) or without (closed bars) ferrozine treatment as detailed in Methods. Values are mean ± SD, n = 7 per group. ***P = 0.0009; ****P < 0.0001; other comparisons are not significantly different. (B) Hemoglobin levels of anemic Sprague–Dawley male rats following 2-week treatment with diets fortified with the different iron compounds: No Fe = control diet with no supplemental iron (3.1 ± 0.6 mg Fe/kgdiet); Fh = synthetic ferrihydrite (35.7 ± 0.1 mg Fe/kgdiet); LM-Fh = tartrate-modified ferrihydrite (31.4 ± 0.5 mg Fe/kgdiet); FeSO4 = Fe(II) sulphate (35.8 ± 0.1 mg Fe/kgdiet). Tartrate-modified ferrihydrite was precipitated from an Fe(III) chloride solution in the presence of tartrate and adipate buffer (Fe/tartrate/adipate = 1:0.5:0.5). Means with a common letter are not statistically different from one another, and means labeled with **** are statistically different from the control diet (No Fe), P < 0.0001, n = 8 per group.

References

    1. De Benoist B., McLean E., Egli I., Cogswell M. World Health Organization; Geneva, Switzerland: 2008. Worldwide prevalence of anaemia 1993-2005.
    1. Ezzati M., Lopez A.D., Rodgers A., Vander Hoorn S., Murray C.J. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360(9343):1347–1360.
    1. WHO . The World Health Report. Reducing risks, promoting healthy life. World Health Organization; Geneva, Switzerland: 2002.
    1. Stoltzfus R.J. Iron deficiency: global prevalence and consequences. Food Nutr Bull. 2003 Dec;24(4 Suppl):S99–S103.
    1. Adamson E.A., Bailey G.R., Richards N., Wilson H. Prevalence of anaemia in an inner city primary school population. Arch Dis Child. 2008;93(5):453.
    1. Barroso F., Allard S., Kahan B.C., Connolly C., Smethurst H., Choo L. Prevalence of maternal anaemia and its predictors: a multi-centre study. Eur J Obstet Gynecol Reprod Biol. 2011 Nov;159(1):99–105.
    1. Sazawal S., Black R.E., Ramsan M., Chwaya H.M., Stoltzfus R.J., Dutta A. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. Lancet. 2006;367(9505):133–143.
    1. Dostal A., Chassard C., Hilty F.M., Zimmermann M.B., Jaeggi T., Rossi S. Iron depletion and repletion with ferrous sulfate or electrolytic iron modifies the composition and metabolic activity of the gut microbiota in rats. J Nutr. 2012;142(2):271–277.
    1. Werner T., Wagner S.J., Martinez I., Walter J., Chang J.S., Clavel T. Depletion of luminal iron alters the gut microbiota and prevents Crohn's disease-like ileitis. Gut. 2011;60(3):325–333.
    1. Carrier J., Aghdassi E., Cullen J., Allard J.P. Iron supplementation increases disease activity and vitamin E ameliorates the effect in rats with dextran sulfate sodium-induced colitis. J Nutr. 2002;132(10):3146–3150.
    1. Navas-Carretero S., Sarria B., Perez-Granados A.M., Schoppen S., Izquierdo-Pulido M., Vaquero M.P. A comparative study of iron bioavailability from cocoa supplemented with ferric pyrophosphate or ferrous fumarate in rats. Ann Nutr Metab. 2007;51(3):204–207.
    1. Moretti D., Zimmermann M.B., Wegmuller R., Walczyk T., Zeder C., Hurrell R.F. Iron status and food matrix strongly affect the relative bioavailability of ferric pyrophosphate in humans. Am J Clin Nutr. 2006;83(3):632–638.
    1. Davidsson L., Kastenmayer P., Szajewska H., Hurrell R.F., Barclay D. Iron bioavailability in infants from an infant cereal fortified with ferric pyrophosphate or ferrous fumarate. Am J Clin Nutr. 2000;71(6):1597–1602.
    1. Zimmermann M.B., Biebinger R., Egli I., Zeder C., Hurrell R.F. Iron deficiency up-regulates iron absorption from ferrous sulphate but not ferric pyrophosphate and consequently food fortification with ferrous sulphate has relatively greater efficacy in iron-deficient individuals. Br J Nutr. 2011;105(8):1245–1250.
    1. Seril D.N., Liao J., Ho K.L., Warsi A., Yang C.S., Yang G.Y. Dietary iron supplementation enhances DSS-induced colitis and associated colorectal carcinoma development in mice. Dig Dis Sci. 2002;47(6):1266–1278.
    1. Radulescu S., Brookes M.J., Salgueiro P., Ridgway R.A., McGhee E., Anderson K. Luminal iron levels govern intestinal tumorigenesis after apc loss in vivo. Cell Rep. 2012;2(2):270–282.
    1. Jin F., Frohman C., Thannhauser T.W., Welch R.M., Glahn R.P. Effects of ascorbic acid, phytic acid and tannic acid on iron bioavailability from reconstituted ferritin measured by an in vitro digestion-Caco-2 cell model. Br J Nutr. 2009;101(7):972–981.
    1. Lonnerdal B., Bryant A., Liu X., Theil E.C. Iron absorption from soybean ferritin in nonanemic women. Am J Clin Nutr. 2006;83(1):103–107.
    1. Zhang L., Fischer W., Pippel E., Hause G., Brandsch M., Knez M. Receptor-mediated cellular uptake of nanoparticles: a switchable delivery system. Small (Weinheim an der Bergstrasse, Germany) 2011;7(11):1538–1541.
    1. Pan Y.H., Sader K., Powell J.J., Bleloch A., Gass M., Trinick J. 3D morphology of the human hepatic ferritin mineral core: new evidence for a subunit structure revealed by single particle analysis of HAADF-STEM images. J Struct Biol. 2009;166(1):22–31.
    1. Wang Z., Li C., Ellenburg M., Soistman E., Ruble J., Wright B. Structure of human ferritin L chain. Acta Crystallogr. 2006;62(Pt 7):800–806.
    1. Barron V., Torrent J., Michel F.M. Critical evaluation of the revised akdalaite model for ferrihydrite—discussion. Am Mineral. 2012;97(1):253–254.
    1. Drits V.A., Sakharov B.A., Salyn A.L., Manceau A. Structural model for ferrihydrite. Clay Miner. 1993;28(2):185–207.
    1. Janney D.E., Cowley J.M., Buseck P.R. Transmission electron microscopy of synthetic 2-and 6-line ferrihydrite. Clay Clay Miner. 2000;48(1):111–119.
    1. Michel F.M., Ehm L., Antao S.M., Lee P.L., Chupas P.J., Liu G. The structure of ferrihydrite, a nanocrystalline material. Science. 2007;316(5832):1726–1729.
    1. Paktunc D., Manceau A., Dutrizac J. Incorporation of Ge in ferrihydrite: implications for the structure of ferrihydrite. American Mineralogist. 2013;98(5–6):848–858.
    1. Pan Y.H., Vaughan G., Brydson R., Bleloch A., Gass M., Sader K. Electron-beam-induced reduction of Fe(3 +) in iron phosphate dihydrate, ferrihydrite, haemosiderin and ferritin as revealed by electron energy-loss spectroscopy. Ultramicroscopy. 2010;110(8):1020–1032.
    1. Johnson J.L., Cannon M., Watt R.K., Frankel R.B., Watt G.D. Forming the phosphate layer in reconstituted horse spleen ferritin and the role of phosphate in promoting core surface redox reactions. Biochemistry. 1999;38(20):6706–6713.
    1. Lopez-Castro J.D., Delgado J.J., Perez-Omil J.A., Galvez N., Cuesta R., Watt R.K. A new approach to the ferritin iron core growth: influence of the H/L ratio on the core shape. Dalton Trans. 2012;41(4):1320–1324.
    1. Bejjani S., Pullakhandam R., Punjal R., Nair K.M. Gastric digestion of pea ferritin and modulation of its iron bioavailability by ascorbic and phytic acids in caco-2 cells. World J Gastroenterol. 2007;13(14):2083–2088.
    1. Kalgaonkar S., Lonnerdal B. Receptor-mediated uptake of ferritin-bound iron by human intestinal Caco-2 cells. J Nutr Biochem. 2009;20(4):304–311.
    1. Hoppler M., Schonbachler A., Meile L., Hurrell R.F., Walczyk T. Ferritin–iron is released during boiling and in vitro gastric digestion. J Nutr. 2008;138(5):878–884.
    1. Kidane T.Z., Sauble E., Linder M.C. Release of iron from ferritin requires lysosomal activity. Am J Physiol Cell Physiol. 2006;291(3):C445–C455.
    1. Masuda H., Ishimaru Y., Aung M.S., Kobayashi T., Kakei Y., Takahashi M. Iron biofortification in rice by the introduction of multiple genes involved in iron nutrition. Sci Rep. 2012;2:543.
    1. Murgia I., Arosio P., Tarantino D., Soave C. Biofortification for combating ‘hidden hunger’ for iron. Trends Plant Sci. 2012;17(1):47–55.
    1. Sperotto R.A., Ricachenevsky F.K., Waldow Vde A., Fett J.P. Iron biofortification in rice: it's a long way to the top. Plant Sci. 2012;190:24–39.
    1. Stein A.J., Meenakshi J.V., Qaim M., Nestel P., Sachdev H.P., Bhutta Z.A. Potential impacts of iron biofortification in India. Soc Sci Med. 2008;66(8):1797–1808.
    1. Powell J, Bruggraber S, Faria N, Pereira D, inventors. Ligand modified poly oxo-hydroxy metal ion materials, their uses and processes for their preparation. U.K. patent WO/2008/096130 2008 06.02.2008.
    1. Cornell R.M., Schwertmann U. Influence of organic-anions on the crystallization of ferrihydrite. Clay Clay Miner. 1979;27(6):402–410.
    1. Raja K.B., Jafri S.E., Dickson D., Acebron A., Cremonesi P., Fossati G. Involvement of iron (ferric) reduction in the iron absorption mechanism of a trivalent iron-protein complex (iron protein succinylate) Pharmacol Toxicol. 2000;87(3):108–115.
    1. Reeves P.G., Nielsen F.H., Fahey G.C., Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr. 1993;123(11):1939–1951.
    1. Hilty F.M., Teleki A., Krumeich F., Buchel R., Hurrell R.F., Pratsinis S.E. Development and optimization of iron- and zinc-containing nanostructured powders for nutritional applications. Nanotechnology. 2009;20(47):475101.
    1. Jambor J.L., Dutrizac J.E. Occurrence and constitution of natural and synthetic ferrihydrite, a widespread iron oxyhydroxide. Chem Rev. 1998;98(7):2549–2586.
    1. Russell J.D. Infrared spectroscopy of ferrihydrite—evidence for the presence of structural hydroxyl-groups. Clay Miner. 1979;14(2):109–114.
    1. Cornell R.L., Schwertmann U. 2nd ed. Wiley-VCH; Weinham: 2003. The iron oxides: structure, preparation, reactions, occurrences and uses.
    1. Pan Y. University of Leeds; Leeds: 2007. Electron microscopy study of mineral cores in ferritin and haemosiderin.
    1. Pan Y., Brown A., Brydson R., Warley A., Li A., Powell J. Electron beam damage studies of synthetic 6-line ferrihydrite and ferritin molecule cores within a human liver biopsy. Micron. 2006;37(5):403–411.
    1. Martell A.E., Smith R.M., Motekaitis R.J. Gaithersburg; National Institute of Standards and Technology: 2004. NIST critically selected stability constants of metal complexes database version 8.0.
    1. Timberlake C.F. Iron–tartrate complexes. J Chem Soc. 1964:1229–1240.
    1. Galloway R., McGuire J. Determinants of compliance with iron supplementation: supplies, side effects, or psychology? Soc Sci Med. 1994;39(3):381–390.
    1. Hyder S.M., Persson L.A., Chowdhury A.M., Ekstrom E.C. Do side-effects reduce compliance to iron supplementation? A study of daily- and weekly-dose regimens in pregnancy. J Health Popul Nutr. 2002;20(2):175–179.
    1. Lund E.K., Wharf S.G., Fairweather-Tait S.J., Johnson I.T. Oral ferrous sulfate supplements increase the free radical-generating capacity of feces from healthy volunteers. Am J Clin Nutr. 1999;69(2):250–255.
    1. Wegmuller R., Zimmermann M.B., Moretti D., Arnold M., Langhans W., Hurrell R.F. Particle size reduction and encapsulation affect the bioavailability of ferric pyrophosphate in rats. J Nutr. 2004;134(12):3301–3304.
    1. Harvey R.S., Reffitt D.M., Doig L.A., Meenan J., Ellis R.D., Thompson R.P. Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron. Aliment Pharmacol Ther. 1998;12(9):845–848.
    1. Michel F.M., Barron V., Torrent J., Morales M.P., Serna C.J., Boily J.F. Ordered ferrimagnetic form of ferrihydrite reveals links among structure, composition, and magnetism. Proc Natl Acad Sci U S A. 2010;107(7):2787–2792.
    1. Geisser P. Safety and efficacy of iron(III)-hydroxide polymaltose complex/a review of over 25 years experience. Arzneimittelforschung. 2007;57(6A):439–452.
    1. Van Wyck D.B., Martens M.G., Seid M.H., Baker J.B., Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007;110(2 Pt 1):267–278.
    1. Lane R.S. Intravenous infusion of iron–dextran complex for iron-deficiency anaemia. Lancet. 1964;1(7338):852–854.
    1. Bisbe E., Garcia-Erce J.A., Diez-Lobo A.I., Munoz M. A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Br J Anaesth. 2011;107(3):477–478.
    1. Lindgren S., Wikman O., Befrits R., Blom H., Eriksson A., Granno C. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol. 2009;44(7):838–845.
    1. Eusterhues K., Wagner F.E., Hausler W., Hanzlik M., Knicker H., Totsche K.U. Characterization of ferrihydrite-soil organic matter coprecipitates by X-ray diffraction and Mossbauer spectroscopy. Environ Sci Technol. 2008;42(21):7891–7897.
    1. Mikutta C. X-ray absorption spectroscopy study on the effect of hydroxybenzoic acids on the formation and structure of ferrihydrite. Geochim Cosmochim Ac. 2011;75(18):5122–5139.
    1. Latunde-Dada G.O., Simpson R.J., McKie A.T. Duodenal cytochrome B expression stimulates iron uptake by human intestinal epithelial cells. J Nutr. 2008;138(6):991–995.
    1. Raja K.B., Simpson R.J., Peters T.J. Investigation of a role for reduction in ferric iron uptake by mouse duodenum. Biochim Biophys Acta. 1992;1135(2):141–146.
    1. Raja K.B., Pountney D., Bomford A., Przemioslo R., Sherman D., Simpson R.J. A duodenal mucosal abnormality in the reduction of Fe(III) in patients with genetic haemochromatosis. Gut. 1996;38(5):765–769.
    1. Wollenberg P., Rummel W. Dependence of intestinal iron absorption on the valency state of iron. Naunyn Schmiedebergs Arch Pharmacol. 1987;336(5):578–582.
    1. Pereira D.I., Mergler B.I., Faria N., Bruggraber S.F., Aslam M.F., Poots L.K. Caco-2 cell acquisition of dietary iron(III) invokes a nanoparticulate endocytic pathway. PLoS One. 2013;8(11):e81250.
    1. Chasteen N.D., Harrison P.M. Mineralization in ferritin: an efficient means of iron storage. J Struct Biol. 1999;126(3):182–194.
    1. Barron V., Torrent J., de Grave E. Hydromaghemite, an intermediate in the hydrothermal transformation of 2-line ferrihydrite into hematite. Am Mineral. 2003;88(11–12):1679–1688.
    1. Deller D.J., Edwards R.G., Dart G., Luke C.G., Davis P.S. Gastric iron binding substance (gastroferrin) in a family with haemochromatosis. Australas Aann Med. 1969;18(1):36–42.
    1. Rudzki Z., Baker R.J., Deller D.J. The iron-binding glycoprotein of human gastric juice. II. Nature of the interaction of the glycoprotein with iron. Digestion. 1973;8(1):53–67.
    1. San Martin C.D., Garri C., Pizarro F., Walter T., Theil E.C., Nunez M.T. Caco-2 intestinal epithelial cells absorb soybean ferritin by mu(2) (AP2)-dependent endocytosis. J Nutr. 2008;138(4):659–666.
    1. Hilty F.M., Arnold M., Hilbe M., Teleki A., Knijnenburg J.T., Ehrensperger F. Iron from nanocompounds containing iron and zinc is highly bioavailable in rats without tissue accumulation. Nat Nanotechnol. 2010;5(5):374–380.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit